- Canada
- /
- Life Sciences
- /
- CNSX:TELI
Telescope Innovations Second Quarter 2025 Earnings: CA$0.013 loss per share (vs CA$0.01 loss in 2Q 2024)
Telescope Innovations (CSE:TELI) Second Quarter 2025 Results
Key Financial Results
- Revenue: CA$1.00m (up 46% from 2Q 2024).
- Net loss: CA$713.3k (loss widened by 32% from 2Q 2024).
- CA$0.013 loss per share (further deteriorated from CA$0.01 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Telescope Innovations shares are down 8.6% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for Telescope Innovations that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Telescope Innovations might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:TELI
Telescope Innovations
A chemical technology company, develops manufacturing processes and tools for the pharmaceutical and chemical industry in the United States and Canada.
Adequate balance sheet low.
Market Insights
Community Narratives

